stay.
Results. The mean intra-operative blood loss (489±281 vs. 339±184 ml, p=0.048) and the decrease in haemoglobin level (38±12 vs. 29±10 g/l, p=0.014) were significantly higher in the control than the treatment group. Two patients among the controls received a transfusion, compared to none in the TA group (p=0.49, Fisher's exact test). The 2 patients who needed blood transfusion had blood losses of 600 and 690 ml, compared to a mean of 489 ml in the whole group. No patient in either group developed deep vein thrombosis or pulmonary embolism up to 3 months. Conclusion. A single dose of intravenous TA (10 mg per kg body weight) given 10 minutes prior to THA is a cost-effective and safe means of minimising blood loss and reduction in haemoglobin concentrations as well as the need for allogenic blood transfusion, without increasing the risk of thromboembolic events.
INTRODUCTION
To avoid allogenic blood transfusions in total hip arthroplasty (THA), various blood-conservation techniques have been developed. Tranexamic acid (TA) has been widely used in surgeries involving fields of gynaecology, cardiology, urology, liver transplant, and dentistry. It inhibits fibrinolysis and reduces blood loss, minimising the need for allogenic blood transfusions after joint arthroplasty and spinal surgery. 1 The effects of TA on intra-and post-operative blood loss in patients undergoing cemented or uncemented THA have been reported. [1] [2] [3] [4] [5] [6] [7] [8] [9] We assessed the effects of a single dose of intravenous TA in patients undergoing THA on intra-operative blood loss, postoperative reduction in haemoglobin and haematocrit levels, blood transfusion, incidence of deep vein thrombosis, and the length of hospital stay.
MATERIALS AND METHODS
Between May 2006 and March 2007, 42 patients underwent primary THA for osteoarthritis by a single surgeon. 10 men and 11 women who did not receive any TA were considered as controls, whereas 9 men and 12 women who received TA constituted the treatment group. Both groups were matched for age, sex, body mass index, and American Society of Anesthesiologists grading. Patients with a history of severe ischaemic heart disease, pulmonary embolism, deep vein thrombosis, hepatic or renal failure, or allergy to TA were excluded.
Four to 6 weeks before surgery, haemoglobin and haematocrit values, platelet counts, and coagulation profiles of the patients were assessed. 10 days before surgery, oral anticoagulants, aspirin, and nonsteroidal anti-inflammatory drugs were stopped. On the evening before surgery, thromboprophylaxis (enoxaparin sodium 0.4 ml) was given subcutaneously and continued after surgery.
Patients were operated on under spinal anaesthesia by a single surgeon using the anterolateral approach. The type of prosthesis used (cemented or uncemented) was based on the surgeon's preference and patient age, activity level and demands. No hybrid prosthesis was used. In cemented THA, the Exeter femoral stem and the Pinnacle acetabular cup systems were used, whereas in uncemented THA, the hydroxyapatite-coated Corail femoral stem and the Pinncale DuoFix acetabular prosthesis were used.
In the treatment group, 10 minutes prior to incision, a single dose of intravenous TA (10 mg per kg body weight) was administered. In both groups, prophylactic antibiotic (cefuroxime) was given intravenously before and after surgery.
Intra-operative blood loss was measured by collection of suction volume and change in the weight (wet vs. dry) of the sponges. No drains were used. Postoperative haemoglobin and haematocrit values were recorded on the morning of postoperative day 2. The decision to transfuse was not entirely based on blood loss or a haemoglobin concentration of <85 g/l; patient age, cardiovascular status and symptoms (if any) were also considered.
For deep vein thrombosis, the patients were assessed clinically for calf swelling, tenderness and oedema of the leg. When clinically indicated, duplex ultrasonography was performed and lowmolecular-weight heparin prescribed. Warfarin was prescribed if deep vein thrombosis was confirmed. At postoperative month 3, patients were assessed for any wound problems or incidence of deep vein thrombosis.
The sample size was determined using data of 2 pilot studies. 2, 10 To detect a mean difference of 225 ml of blood loss with a standard deviation of 200 ml, with a power of 90% and a type-one error probability of 5%, a minimum of 18 patients in each group were needed. Differences between groups were compared using the Chi squared test, Fisher's exact test, t test and Mann-Whitney U test where appropriate. Preand post-operative blood indices were compared using the paired t test. A p value of <0.05 was considered significant.
RESULTS
The mean intra-operative blood loss (489±281 vs. 339±184 ml, p=0.048) and the decrease in haemoglobin level (38±12 vs. 29±10 g/l, p=0.014) were significantly higher in the control than the treatment group (Table) . Two patients among the controls received a transfusion, compared to none in the TA group (p=0.49, Fisher's exact test). The 2 patients who needed blood transfusion had blood losses of 600 and 690 ml, compared to a mean of 489 ml in the whole group. No patient in either group developed deep vein thrombosis or pulmonary embolism up to 3 months.
DISCUSSION
TA inhibits fibrinolysis mainly by blocking the lysinebinding sites of plasminogen.
11 Plasminogen binds to fibrin at this site and results in clot breakdown. Tissue plasminogen activator is a major enzyme responsible for conversion of plasminogen into active plasmin. Surgery and venous stasis increase the release of tissue plasminogen activator and activate the fibrinolytic system. Binding of TA to plasminogen prevents the breakdown of fibrin even though plasmin is generated. 11 For TA to be effective, it has to interact with the plasminogen binding site before binding to fibrin takes place. 10, 12 The fibrinolytic response after surgery is biphasic. 4, 13 The initial phase of increased fibrinolytic activity lasts one hour and is followed by fibrinolytic shutdown, which peaks again after about 24 hours. This is a consequence of increased release of plasminogen activator inhibitor.
The elimination half life of intravenous TA is 2 hours, and it has a volume of distribution of 9 to 12 litres. 11 Once plasminogen is bound to the fibrin surface, TA is no longer effective. 13 TA had little effect when administered at the end of surgery and 3 hours later; reduction in blood loss after THA was not significant. 10, 11 TA inhibited clot lysis more effectively when it was added before clot formation. 12 TA reduced blood loss during and after THA when 2 doses of TA (10 mg/kg) were administered just before incision and 3 hours later (and continued for 10 hours at a dosage of 1 mg/kg/h), together with intra-operative autotransfusion. 8 Nonetheless, other studies reported no significant reduction in intraoperative blood loss. 3, 5 Significant reduction in postoperative (but not intra-operative) blood loss was associated with a single bolus of TA (10 mg/kg) administered immediately before the operation, 2 or 3 doses (each of 10 mg/kg) given at the operation, and 8 and 16 hours later. 9 In uncemented THA patients, a TA bolus of 1000 mg 5 minutes before the operation was associated with reduced postoperative (but not intra-operative) blood loss in the first 4 hours.
14 There was no definite answer with regard to effective dosage and pattern. Nonetheless, its use significantly reduced intra-and post-operative blood loss, 6 and the need for blood transfusions.
2-5,9,15 TA was associated with lower allogenic blood transfusion rates and blood loss in hip and knee arthroplasty patients.
6,7 1000 mg of TA costs £1.55, whereas a unit of blood costs £133. Avoidance of allogenic blood transfusions has economic benefits and minimises the risk of related infections and other adverse reactions, [16] [17] [18] [19] and is associated with reduced morbidity and shorter hospital stays. 18, 20, 21 The use of TA increases the risk of thromboembolic events (especially deep vein thrombosis). Nonetheless, in our study, such increases were not observed, which is consistent with other findings reported in * Mann-Whitney U test 6, 7 The use of TA is not associated with increased thromboembolic events, because the effects of TA are more pronounced in operative wounds than in peripheral venous blood. This is because generation of tissue plasminogen activator (activating the fibrinolytic pathway) ensues in wounds. 2, 11, 21 Thus, TA acts as a clot stabiliser and not a clot promoter.
Cemented prostheses are associated with less blood loss, 6, 22 as cement prevents bleeding from the medullary canal. Nonetheless, blood transfusion in patients treated with cemented or uncemented prostheses were similar. 23 TA has also been shown to reduce blood loss associated with cardiopulmonary bypass surgery by 30 to 40%. 11, 24 In cardiac surgery its use was associated with a reduction in peri-operative blood loss and allogenic transfusion. 25 Most studies used 10 mg/kg bolus injections immediately before surgery, and continued at a rate of 1 mg/kg for 10 to 12 hours. TA administered before and during in primary coronary artery bypass operations was associated with more effective reduction in blood loss and transfusions. 26 Thus, TA is a cost-effective and safe means of minimising blood loss and reductions in haemoglobin concentrations, as well as the need for allogenic blood transfusion, without increasing the risk of thromboembolic events.
